ReviewFrontiers in medicine2022
Collapsing Glomerulopathy: A Review by the Collapsing Brazilian Consortium.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Immune Deposits, Complement Activation, and <italic>APOL1</italic> Risk Variants in Focal Segmental Glomerulosclerosis.American journal of nephrology · 2026Article
- A Young Man with Hematuria, Proteinuria, and Acute Kidney Injury Following an Upper Respiratory Infection.Kidney360 · 2026Article
- Molecular mechanisms in podocytopathies: finding suitable targets for a new era of glomerular gene therapy.Clinical kidney journal · 2026Review
- Uncertainties in post-COVID renal outcomes: need for refined surveillance.International urology and nephrology · 2025Article
- Collapsing Glomerulopathy in Brazil: A Nationwide Descriptive Study.Nephrology (Carlton, Vic.) · 2025Article
- Dengue Infection as a Trigger for Collapsing Glomerulopathy in Patients WithKidney international reports · 2025Article
- Targeting Diabetic Complications through Oleuropein-Mediated Enzyme Modulation: A Chemical Biology Study in the Human-Relevant ModelACS omega · 2025Article
- An Unusual Association: Collapsing Glomerulonephritis in a Patient With Type 1 Diabetes.Cureus · 2025Article
- Nephrotic and Non-Nephrotic Focal Segmental Glomerulosclerosis: Clinical Characteristics, Etiology, and Columbia Classification.Diagnostics (Basel, Switzerland) · 2025Article
- What is the spectrum of kidney pathology associated with COVID-19?Internal medicine journal · 2024Review
- Kidney damage associated with COVID-19: from the acute to the chronic phase.Renal failure · 2024Review
- Tip Lesion Most Frequent FSGS Variant Related to COVID-19 Vaccine: Two Case Reports and Literature Review.Vaccines · 2024Article
- CMV-associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient.Pediatric transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collapsing glomerulopathy (CG) is a clinicopathologic entity characterized by segmentar or global collapse of the glomerulus and hypertrophy and hyperplasia of podocytes. The Columbia classification of 2004 classified CG as a histological subtype of focal segmental glomerulosclerosis (FSGS). A growing number of studies have demonstrated a high prevalence of CG in many countries, especially among populations with a higher proportion of people with African descent. The present study is a narrative review of articles extracted from PubMed, Medline, and Scielo databases from September 1, 2020 to December 31, 2021. We have focused on populational studies (specially cross-sectional and cohort articles). CG is defined as a podocytopathy with a distinct pathogenesis characterized by strong podocyte proliferative activity. The most significant risk factors for CG include
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.